3,4,5-Trifluoro-2-iodoaniline | 1373439-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4,5-Trifluoro-2-iodoaniline
• CAS: 1373439-17-8
• 化学式: C₆H₃F₃IN
• 分子量: 272.996
• InChiKey: UDPIRDLCIWUKDR-UHFFFAOYSA-N

物化性质

• 沸点：
  255.0±40.0 °C(Predicted)
• 密度：
  2.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4,5-Trifluoro-2-iodoaniline 在 三乙烯二胺 、 palladium diacetate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 作用下， 以 四氢呋喃 、 丙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 82.17h， 生成 3-hydroxy-N-[(E)-1-(4,5,6-trifluoro-1H-indol-2-yl)propylideneamino]naphthalene-2-carboxamide
  参考文献：
  名称：

  Optimization and structure–activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents

  摘要：

  A novel series of hydrazones were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK has been identified as one of the most highly connected 'hub proteins' in MRSA. PK has been shown to be critical for bacterial survival which makes it a potential target for development of novel antibiotics and the high degree of connectivity implies it should be very sensitive to mutations and thus less able to develop resistance. PK is not unique to bacteria and thus a critical requirement for such a PK inhibitor would be that it does not inhibit the homologous human enzyme(s) at therapeutic concentrations. Several MRSA PK inhibitors (including 8d) were identified using in silico screening combined with enzyme assays and were found to be selective for bacterial enzyme compared to four human PK isoforms (M1, M2, R and L). However these lead compounds did not show significant inhibitory activity for MRSA growth presumably due to poor bacterial cell penetration. Structure-activity relationship (SAR) studies were carried out on 8d and led us to discover more potent compounds with enzyme inhibiting activities in the low nanomolar range and some were found to effectively inhibit bacteria growth in culture with minimum inhibitory concentrations (MIC) as low as 1 mu g/mL. These inhibitors bind in two elongated flat clefts found at the minor interfaces in the homo-tetrameric enzyme complex and the observed SAR is in keeping with the size and electronic constraints of these binding sites. Access to the corresponding sites in the human enzyme is blocked. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.002
• 作为产物：
  描述：

  3,4,5-三氟苯胺 在 盐酸 、 potassium iodide 作用下， 以 甲醇 、 水 为溶剂， 以37%的产率得到3,4,5-Trifluoro-2-iodoaniline
  参考文献：
  名称：

  氢键增强卤素键的理论、固态和溶液量化

  摘要：

  近端非共价力在自然系统中很常见，了解它们并置的后果至关重要。本文首次通过实验量化了氢键增强卤素键 (HBeXB)，而没有蛋白质结构或预组织的复杂性。HBeXB 是卤素键，当卤素供体同时接受氢键时，卤素键得到加强。我们的理论研究表明，富电子卤素键供体通过相邻的氢键得到加强。此外，更强的氢键供体最能增强卤素键。卤化物配合物 (X - =Br - , I - )的 X 射线晶体结构表明 HBeXB 产生的卤素键比非氢键类似物短。用氯化物进行的19 F NMR 滴定突出表明 HBeXB 类似物表现出更强的结合力。这些结果共同构成了未来研究密切接近的氢键和卤素键的基础。

  DOI：

  10.1002/anie.202012262
• 作为试剂：
  描述：

  碘 、 3,4,5-三氟苯胺 在 silver(II) sulfate 3,4,5-Trifluoro-2-iodoaniline 、 crude residue 、 silica gel 、 eluent 、 乙酸乙酯 、 正庚烷 作用下， 以 乙醇 为溶剂， 以to yield 0.279 g (42%) of 3,4,5-trifluoro-2-iodoaniline as a white solid的产率得到3,4,5-Trifluoro-2-iodoaniline
  参考文献：
  名称：

  Compounds for the treatment of neurodegenerative diseases

  摘要：

  本发明提供了新型化合物及其作为药物的使用，更具体地用于预防或治疗神经退行性疾病，更具体地说是某些神经疾病，如被统称为tau病变的疾病和由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用所述新型化合物制备用于治疗这些神经退行性疾病的药物。本发明还涉及包括所述新型化合物的制药组合物以及制备所述新型化合物的方法。化合物的化学式为（A1），其中R1，R2，R4，R5，R6，E，n，Y1，Y2，Y3，Y4，Y5，B，R8和m如权利要求所定义。

  公开号：

  US09284271B2

文献信息

• NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130289033A1

  公开（公告）日：2013-10-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R 1 , R 2 , R 4 , R 5 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m如权利要求中所定义。
• [EN] NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2012080221A1

  公开（公告）日：2012-06-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R6、E、n、Y1、Y2、Y3、Y4、Y5、L、B、R8和m如权利要求中所定义。
• NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130274260A1

  公开（公告）日：2013-10-17

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R 1 , R 2 , R 4 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , L, B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及使用这些新型化合物来制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括这些新型化合物的药物组合物以及制备这些新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R6、E、n、Y1、Y2、Y3、Y4、Y5、L、B、R8和m如权利要求中所定义。
• [EN] NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2012080220A1

  公开（公告）日：2012-06-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

  这项发明提供了新颖的化合物，以及这些新颖的化合物用作药物，更具体地用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病变的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成为特征的疾病。本发明还涉及利用这些新颖的化合物制备对治疗这种神经退行性疾病有用的药物。本发明还涉及包括这些新颖化合物的药物组合物，以及这些新颖化合物的制备方法。这些化合物的化学式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m的定义如索赔中所述。
• N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders
  申请人：Katholieke Universiteit Leuven

  公开号：EP2651887B1

  公开（公告）日：2016-08-24